Azacitidine

Details About Generic Salt ::  Azacitidine 

Main Medicine Class:: #N/A   Sub Medicine Class ::  #N/A

18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS
AZACITIDINE
DNA METHYLATION INHIBITOR | ANTI-NEOPLASTIC
PK: A: SC: Rapid & complete D: Vd: 76±26 L(IV) M: Hepatic E: Urine (50-85%), feces (minor)

Indications & Dose: MYELODYSPLASTIC SYNDROME IV/SC Adult 75mg/m2/day for 1 wk repeated q 4wks, dose may increase to 100mg/m2/day (if no benefits is observed after 2cycles/no toxicity other than nausea/vomiting)

Contra: Hypersensitivity, Advanced malignant hepatic tumors

Precautions: Renal impairment

ADR: Serious: Peripheral edema, chest pain, pallor, pitting edema, hypokalemia, thrombocytopenia, leukopenia, febrile neutropenia, myelosuppression, arthralgia, myalgia, URTI, pneumonia, hypertension, hypotension, tachycardia, cellulitis, hemorrhoids, hematoma, herpes simplex, lymphadenopathy, post procedural hemorrhage, Others: fever, fatigue, dizziness, depression, insomnia, pain, bruising, erythema, skin lesion, nausea, vomiting, constipation, weight loss, abdominal pain, injection site reaction, weakness, back pain, dyspnea, nasopharyngitis, epistaxis, crackles, gingival bleeding, stomatitis, weight loss, dysphagia, abdominal distension, rhinorrhea, wheezing, nasal congestion, sinusitis, night sweats, tongue ulceration, mouth hemorrhage

DDI: Others Pimecrolimus/Denosumab/Tacrolimus increases azacitidne levels, Vaccines (Live & inactivated)/BCG levels decreases, Vaccines (Live)/Leflunomide levels increases

Monitor: LFTs, electrolytes, CBC with differential & platelets, renal function test

Related Posts:
You May Also Like::